Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: Results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Annals of the Rheumatic Diseases

Volumn 77, Issue 9, 2018, Pages 1295-1302

  Baeten, Dominique ^a   Østergaard, Mikkel ^b,c   Wei, James Cheng Chung ^d,e   Sieper, Joachim ^f   Järvinen, Pentti ^g   Tam, Lai Shan ^h   Salvarani, Carlo ^i,j   Kim, Tae Hwan ^k   Solinger, Alan ^l   Datsenko, Yakov ^m   Pamulapati, Chandrasena ^l   Visvanathan, Sudha ^l   Hall, David B ^l   Aslanyan, Stella ^l   Scholl, Paul ^l   Padula, Steven J ^m  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g Kiljavan Lääketutkimus Oy   (Finland)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ IRCCS   (Italy)

^j UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^k Hanyang University College of Medicine   (South Korea)

^l BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^m BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

more..

Author keywords

ankylosing spondylitis; DMARDs (biologic); treatment

Indexed keywords

CREATINE KINASE; PLACEBO; RISANKIZUMAB; ANTIRHEUMATIC AGENT; INTERLEUKIN 23P19; MONOCLONAL ANTIBODY;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTICLE; ASSESSMENT IN SPONDYLO ARTHRITIS INTERNATIONAL SOCIETY; BACKACHE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL OUTCOME; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ECZEMA; FATIGUE; FEMALE; HEADACHE; HUMAN; INFLUENZA; KIDNEY COLIC; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; TREATMENT DURATION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PROOF OF CONCEPT; REMISSION; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-23 SUBUNIT P19; MALE; MIDDLE AGED; PROOF OF CONCEPT STUDY; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; YOUNG ADULT;

EID: 85049171519     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2018-213328     Document Type: Article

References (31)

1. D ougados M, Baeten D. Spondyloarthritis. Lancet 2011;377:2127-37.
2. Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015;373:2534-48.
3. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 2016;68:282-98.
4. van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978-91.
5. P aine A, Ritchlin CT. Targeting the interleukin-23/17 axis in axial spondyloarthritis. Curr Opin Rheumatol 2016;28:359-67.
6. R eveille JD, Sims AM, Danoy P, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 2010;42:123-7.
7. Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14, 500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329-37.
8. Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc Natl Acad Sci U S A 2011;108:9560-5.
9. Appel H, Maier R, Bleil J, et al. In situ analysis of interleukin-23-and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum 2013;65:1522-9.
10. Kenna TJ, Davidson SI, Duan R, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive /T cells in patients with active ankylosing spondylitis. Arthritis Rheum 2012;64:1420-9.
11. Zhang L, Li YG, Li YH, et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One 2012;7:e31000.
12. Zeng L, Lindstrom MJ, Smith JA. Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response. Arthritis Rheum 2011;63:3807-17.
13. Benham H, Rehaume LM, Hasnain SZ, et al. Interleukin-23 mediates the intestinal response to microbial-1, 3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol 2014;66:1755-67.
14. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-t+ CD3+CD4-CD8-entheseal resident T cells. Nat Med 2012;18:1069-76.
15. Gaffen SL, Jain R, Garg AV, et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 2014;14:585-600.
16. Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: A randomised, double-blind, placebo-controlled trial. Lancet 2013;382:1705-13.
17. Baraliakos X, Borah B, Braun J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: An observational study. Ann Rheum Dis 2016;75:408-12.
18. Singh S, Kroe-Barrett RR, Canada KA, et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs 2015;7:778-91.
19. Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2015;136:116-24.
20. P app KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med 2017;376:1551-60.
21. Feagan BG, Sandborn WJ, D'Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: A randomised, double-blind, placebo-controlled phase 2 study. Lancet 2017;389:1699-709.
22. Mease PJ, Kellner H, Morita A, et al. Efficacy and safety results from a phase 2 trial of risankizumab, a selective IL-23p19 inhibitor, in patients with active psoriatic arthritis. Arthritis Rheumatol 2017;69(Suppl 10).
23. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
24. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
25. Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 2005;53:703-9.
26. Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum 2005;53:502-9.
27. Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47-53.
28. P oddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, openlabel, proof-of-concept study (TOP AS). Ann Rheum Dis 2014;73:817-23.
29. Gracey E, Qaiyum Z, Almaghlouth I, et al. IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis 2016;75:2124-32.
30. Mangan PR, Su LJ, Jenny V, et al. Dual inhibition of interleukin-23 and interleukin-17 offers superior efficacy in mouse models of autoimmunity. J Pharmacol Exp Ther 2015;354:152-65.
31. Secukinumab Prescribing information. Highlights of prescribing information. https:// www. pharma. us. novartis. com/ sites/ www. pharma. us. novartis. com/ files/ cosentyx. pdf (accessed 20 Feb 2018).